Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

B0200000

Baclofen

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(±)-Baclofen, (±)-β-(Aminomethyl)-4-chlorobenzenepropanoic acid, Lioresal

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C10H12ClNO2
CAS Number:
1134-47-0
Molecular Weight:
213.66
MDL number:
MFCD00055143
UNSPSC Code:
41116107
PubChem Substance ID:
329773100
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

baclofen

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

ClC1=CC=C(C(CN)CC(O)=O)C=C1

InChI

1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)

InChI key

KPYSYYIEGFHWSV-UHFFFAOYSA-N

Gene Information

human ... GABBR1(2550) , GABBR2(9568)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Baclofen EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

GABAB receptor agonist; skeletal muscle relaxant; antispastic agent.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A C Miracle et al.
AJNR. American journal of neuroradiology, 32(7), 1158-1164 (2010-10-30)
ITB pumps are widely used in the treatment of intractable spasticity for many clinical indications, including cerebral palsy and spinal cord injury. High-dose intrathecal administration places the patient at significant risk for withdrawal in the event of device malfunction, necessitating
Andrew J Muzyk et al.
CNS drugs, 26(1), 69-78 (2011-12-08)
The pharmacological properties of baclofen, a GABA(B) receptor agonist, have led to investigation of its use for the off-label treatment of alcohol dependence. Literature examining the role of baclofen in alcohol dependence suggests that it may be a useful medication
Laura A Bonouvrié et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 16(3), 279-284 (2011-10-22)
Intrathecal baclofen (ITB) treatment is frequently used for individuals with severe, but non-progressive, spasticity refractory to oral treatment. However, experiences with ITB in patients with progressive neurological disorders of childhood causing spasticity are limited. To investigate whether ITB is an
April Erwin et al.
Multiple sclerosis (Houndmills, Basingstoke, England), 17(5), 623-629 (2011-02-02)
The majority of patients with multiple sclerosis (MS) have symptoms of spasticity that increasingly impair function as the disease progresses. With appropriate treatment, however, quality of life can be improved. Oral antispasticity medications are useful in managing mild spasticity but
Amanda McIntyre et al.
The journal of spinal cord medicine, 37(1), 11-18 (2013-10-05)
To review the available evidence on the effectiveness of intrathecal baclofen in the treatment of spasticity in individuals with spinal cord injuries (SCIs) at least 6 months post-injury or diagnosis. A literature search of multiple databases (Pub Med, CINAHL, EMBASE)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service